Evidence map›Paper›PMID 42809394›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Biosynthetic origin of anticancer dolastatin 15 reveals a noncanonical NRPS architecture enabling 2-keto acid activation.

Manyun Chen, Jie Liu, Hsin-Ying Tsai, Cheng-Yu Li, Jeremiah D Batucan, Campbell W Eckhardt, Tam H D Pham, Emma K Ellis, Ranjala Ratnayake, Valerie J Paul and 4 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Manyun ChenDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery, and Development, University of Florida, Gainesville, FL 32610.ORCID 0000-0001-6803-044X
Jie LiuDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544.
Hsin-Ying TsaiDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery, and Development, University of Florida, Gainesville, FL 32610.ORCID 0009-0002-8724-5627
Cheng-Yu LiDepartment of Chemistry, University of Florida, Gainesville, FL 32611.ORCID 0000-0003-1027-4649
Jeremiah D BatucanDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery, and Development, University of Florida, Gainesville, FL 32610.ORCID 0000-0003-1238-9415
Campbell W EckhardtDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery, and Development, University of Florida, Gainesville, FL 32610.ORCID 0009-0003-5319-9834
Tam H D PhamDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery, and Development, University of Florida, Gainesville, FL 32610.
Emma K EllisDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery, and Development, University of Florida, Gainesville, FL 32610.
Ranjala RatnayakeDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery, and Development, University of Florida, Gainesville, FL 32610.ORCID 0000-0002-5980-2070
Valerie J PaulSmithsonian Marine Station, Fort Pierce, FL 34949.ORCID 0000-0002-4691-1569
Steven D BrunerDepartment of Chemistry, University of Florida, Gainesville, FL 32611.ORCID 0000-0002-0522-480X
Mohamed S DoniaDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544.ORCID 0000-0002-9604-2912
Hendrik LueschDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery, and Development, University of Florida, Gainesville, FL 32610.ORCID 0000-0002-4091-7492
Yousong DingDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery, and Development, University of Florida, Gainesville, FL 32610.ORCID 0000-0001-8610-0659

Funding

X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Vivian Stojanoff · 2019 to 2026
$38.6M
Integrative Multidisciplinary Discovery Platform to Unlock Marine Natural Products Therapeutic OpportunitiesRM1GM145426 · NIGMS · UNIVERSITY OF FLORIDA · PI Mohamed Abou Donia, Steven D Bruner · 2022 to 2026
$8.8M
NIH Equipment Supplement to R35GM128742R35GM128742 · NIGMS · UNIVERSITY OF FLORIDA · PI Yousong Ding · 2018 to 2026
$3.4M
HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35GM128742HHS | NIH | National Institute of General Medical Sciences (NIGMS) RM1GM145426NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R35 GM128742NIGMS NIH HHS RM1 GM145426NSF | NSF Graduate Research Fellowship Program (GRFP) AWD13127-2236414
6 · The paper itself

Abstract

Elucidating the biological origins and biosynthetic pathways of marine natural products remains a major challenge, particularly for compounds derived from microbial consortia. Here, we identify the marine cyanobacterial genus

Indexed as

Antineoplastic AgentsCyanobacteriaDepsipeptidesPeptide SynthasesBiosynthetic PathwaysGenome, BacterialMultigene FamilyPhylogenyAntineoplastic AgentsDepsipeptidesdolastatin 15non-ribosomal peptide synthasePeptide Synthasesdolastatin 15enzyme evolutiongenome-resolved metagenomicsnatural product biosynthesisnonribosomal peptide synthetase

Identifiers

PMID42809394
PMCPMC13643306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.